ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.
The ACC has published an Expert Consensus Decision Pathway which provides practical recommendations on lifestyle modifications in patients with hypertriglyceridemia and use of statins and TG risk-based non-statin therapies for ASCVD risk reduction.
This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.
ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.
ACC 2021 A phase 2 study showed that evinacumab resulted in reduction of TGs in patients with severe hypertriglyceridemia, but lowering was variable and dependent on genotype.
Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.
Icosapent ethyl has received EC approval to reduce CV risk in high-risk statin-treated patients who have elevated triglycerides and either established CVD or diabetes and ≥1 additional CV risk factor.
Following the results from the REDUCE-IT trial, the CHMP of the EMA has issued a positive recommendation for icosapent ethyl to reduce CV events in patients with established CVD or with diabetes and an additional risk factor.
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.
In a prospective study using data from the Copenhagen General Population Study, VLDL cholesterol explained 50% of risk in the association between apoB-containing lipoproteins and MI, whereas VLDL triglycerides did not contribute to this risk.
This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.
Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.